A drug originally designed to target cancer has been found to restore memory and reverse cognitive problems in mice with Alzheimer’s disease-like symptoms and could offer a path forward to a treatment for humans someday, a new study found.

Yale University researchers found that the previously approved drug, saracatinib, targeted beta amyloid deposits and reduced their toxic effect on surrounding brain cells. The buildup of beta amyloid in the brain can be a precursor of Alzheimer’s disease in the aging brain.

READ FULL ARTICLE Curated publisher From Washington Post